title: Adenocarcinoma has an excellent outcome with pemetrexed treatment in Korean patients: a prospective, multicenter trial.
abstract: OBJECTIVE
  This prospective multicenter study conducted by the Korean Cancer Study Group evaluated the efficacy and safety of pemetrexed in Korean patients with advanced non-small cell lung cancer (NSCLC) who had prior chemotherapy.
  
  
  METHODS
  Patients with stage IIIB or IV NSCLC in whom prior chemotherapy failed received pemetrexed 500 mg/m(2) every 3 weeks with folic acid and vitamin B12 supplementation until disease progression or the development of intolerable toxicity. Eighty-one patients were enrolled.
  
  
  RESULTS
  The overall response rate for 78 evaluable patients was 5.1% [95% confidence interval (CI) 1.4-12.6; partial response 4/78, no complete response]. The disease control rate including complete, partial response and stable disease was 46.2% (36/78, 95% CI 34.8-57.8). With a median 8.7 months follow-up, the median time to progression was 3.1 months (95% CI 1.17-5.03) and the median overall survival (OS) was 7.8 months (95% CI 5.19-10.35). The median OS for patients with adenocarcinoma histology was 18.7 months compared to 6.1 months for non-adenocarcinoma. In a multivariate analysis, Eastern Cooperative Oncology Group performance status 0-1 [hazards ratio (HR)=0.331, 95% CI 0.135-0.814] and adenocarcinoma (HR=0.504, 95% CI 0.283-0.899) were independent factors for prolongation of overall survival.
  
  
  CONCLUSIONS
  Pemetrexed monotherapy has promising efficacy in patients with advanced NSCLC as a second-line therapy with less hematologic and non-hematologic toxicity, especially in those with adenocarcinoma histology.
authors.affiliation: Department of Internal Medicine, Kangwon National University Hospital, Kangwon National University School of Medicine, Chuncheon 200-722, Republic of Korea.
authors.forename: Hui-Young
authors.initials: HY
authors.lastname: Lee
authors.forename: Myung-Ju
authors.initials: MJ
authors.lastname: Ahn
authors.forename: Yeon Hee
authors.initials: YH
authors.lastname: Park
authors.forename: Jin Seok
authors.initials: JS
authors.lastname: Ahn
authors.forename: Bong-Seog
authors.initials: BS
authors.lastname: Kim
authors.forename: Hoon Kyo
authors.initials: HK
authors.lastname: Kim
authors.forename: Heung Tae
authors.initials: HT
authors.lastname: Kim
authors.forename: Hun Mo
authors.initials: HM
authors.lastname: Ryoo
authors.forename: Sung Hwa
authors.initials: SH
authors.lastname: Bae
authors.forename: Seung Sei
authors.initials: SS
authors.lastname: Lee
authors.forename: Kwon
authors.initials: K
authors.lastname: Choi
authors.forename: Dae-Sik
authors.initials: DS
authors.lastname: Hong
authors.forename: Kyung Hee
authors.initials: KH
authors.lastname: Lee
authors.forename: Jung Hye
authors.initials: JH
authors.lastname: Kwon
authors.forename: In Shil
authors.initials: IS
authors.lastname: Choi
authors.forename: Byung-Su
authors.initials: BS
authors.lastname: Kim
authors.forename: Nam Su
authors.initials: NS
authors.lastname: Lee
authors.forename: Soo Jung
authors.initials: SJ
authors.lastname: Gong
authors.forename: Keunchil
authors.initials: K
authors.lastname: Park
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D005260:Female; D005971:Glutamates / Q000008:administration & dosage* / Q000009:adverse effects; D006147:Guanine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D006801:Humans; D007723:Korea; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D000068437:Pemetrexed; D011446:Prospective Studies; D016019:Survival Analysis
chemical_list: D000970:Antineoplastic Agents; D005971:Glutamates; D000068437:Pemetrexed; D006147:Guanine